ACADIA Pharmaceuticals Inc (ACAD) Stock Analysis
Verdict: HOLD
Commercial growth in Daybue/Nuplazid provides solid cash flow, but imminent Phase 2 remlifanserin readout creates binary swing risk.
Investment score: 61/100
Analysis as of
Is ACADIA Pharmaceuticals Inc stock worth reviewing? AI model thesis
The AI model rates ACADIA Pharmaceuticals as a HOLD (Score: 61/100). Robust cash flow from NUPLAZID and DAYBUE plus $956M in total liquidity protect fundamental valuation, but technical momentum is negative and upcoming Phase 2 trial readouts introduce sharp binary risk.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
ACADIA Pharmaceuticals Inc opportunities and risks
What speaks for ACAD
- Commercial expansion of DAYBUE (trofinetide) in Rett syndrome
What speaks against ACAD
- Clinical trial failure for remlifanserin in Alzheimer's disease psychosis
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ACAD | 9.1x | 3.1x | 27.6x | 91.1% | 33.4% | 5.0% |
| LEGN | n/a | 2.7x | n/a | 56.6% | -7.2% | -7.4% |
| IDYA | n/a | 15.5x | n/a | -13.3% | -74.8% | -5.2% |
| VCYT | 31.4x | 6.4x | 25.8x | 72.1% | 20.4% | 4.6% |
| ARQT | 123.8x | 7.4x | 79.3x | 91.1% | 6.1% | 1.1% |
| DNLI | n/a | 923.9x | n/a | -61.0% | -14191.2% | -13.1% |
| Peer median | n/a | 7.4x | n/a | 56.6% | -7.2% | -5.2% |
Frequently asked questions about ACADIA Pharmaceuticals Inc (ACAD)
Is ACAD stock a good investment?
The cached TradeMates AI model rates ACADIA Pharmaceuticals Inc as HOLD with an investment score of 61/100. The AI model rates ACADIA Pharmaceuticals as a HOLD (Score: 61/100). Robust cash flow from NUPLAZID and DAYBUE plus $956M in total liquidity protect fundamental valuation, but technical momentum is negative and upcoming Phase 2 trial readouts introduce sharp binary risk. This is algorithmic model output, not personal investment advice.
Is ACAD stock a buy?
The TradeMates model verdict for ACAD is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.